KRYS Stock Price, Krystal Biotech Inc Quote, Chart

Market Summary

USD154.60-0.16

Market Closed

-0.10%

KRYS Alerts

Big jump in Revenue (Y/Y)

Big jump in Earnings (Y/Y)

KRYS Stock Price

View Fullscreen

KRYS RSI Chart

KRYS Valuation

Market Cap

4.4B

Price/Earnings (Trailing)

77.24

Price/Sales (Trailing)

87.09

EV/EBITDA

226.55

Price/Free Cashflow

-81.1

KRYS Price/Sales (Trailing)

KRYS Profitability

EBT Margin

25.44%

Return on Equity

7.15%

Return on Assets

6.7%

Free Cashflow Yield

-1.23%

KRYS Fundamentals

KRYS Revenue

Revenue (TTM)

50.7M

Rev. Growth (Yr)

957.49%

Rev. Growth (Qtr)

7.37%

KRYS Earnings

Earnings (TTM)

57.2M

Earnings Growth (Yr)

102.06%

Earnings Growth (Qtr)

-89.28%

Breaking Down KRYS Revenue

Last 7 days

-1.5%

Last 30 days

-10.9%

Last 90 days

42.2%

Trailing 12 Months

75.4%

How does KRYS drawdown profile look like?

KRYS Financial Health

Current Ratio

12.66

KRYS Investor Care

Shares Dilution (1Y)

10.69%

Diluted EPS (TTM)

2.03

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	50.7M
2018	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Krystal Biotech Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 11, 2024	krishnan suma	sold	-4,274,040	170	-25,000	president, r&d
Mar 11, 2024	krishnan krish s	sold	-4,274,040	170	-25,000	president and ceo
Mar 11, 2024	krishnan krish s	sold	-4,273,680	170	-25,000	president and ceo
Mar 11, 2024	krishnan suma	sold	-4,273,680	170	-25,000	president, r&d
Feb 28, 2024	krishnan krish s	acquired	-	-	7,500	president and ceo
Feb 28, 2024	krishnan krish s	sold (taxes)	-566,051	163	-3,471	president and ceo
Feb 28, 2024	romano kathryn	acquired	470,270	63.55	7,400	chief accounting officer
Feb 28, 2024	krishnan suma	acquired	-	-	7,500	president, r&d
Feb 28, 2024	romano kathryn	sold (taxes)	-377,367	163	-2,314	chief accounting officer
Feb 28, 2024	krishnan suma	sold (taxes)	-943,418	163	-5,785	president, r&d

Which funds bought or sold KRYS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	Jackson Creek Investment Advisors LLC	new	-	1,142,000	1,142,000	0.41%
May 10, 2024	CITIGROUP INC	added	42.53	4,736,980	9,273,360	0.01%
May 10, 2024	MACKENZIE FINANCIAL CORP	new	-	241,451	241,451	-%
May 10, 2024	Pacer Advisors, Inc.	new	-	44,838	44,838	-%
May 10, 2024	PIER 88 INVESTMENT PARTNERS LLC	unchanged	-	63,028	208,178	0.05%
May 10, 2024	LPL Financial LLC	sold off	-100	-205,319	-	-%
May 10, 2024	JPMORGAN CHASE & CO	reduced	-17.98	4,671,000	31,160,200	-%
May 10, 2024	GROUP ONE TRADING, L.P.	new	-	212,093	212,093	-%
May 10, 2024	Cynosure Group, LLC	new	-	670,262	670,262	0.12%
May 10, 2024	OSAIC HOLDINGS, INC.	reduced	-65.24	-45,090	44,837	-%

Are Funds Buying or Selling KRYS?

Are funds buying KRYS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KRYS

No. of Funds

Unveiling Krystal Biotech Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	avoro capital advisors llc	9.1%	2,565,555	SC 13G/A
Feb 14, 2024	redmile group, llc	6.1%	1,733,189	SC 13G/A
Feb 13, 2024	vanguard group inc	8.64%	2,435,774	SC 13G
Feb 12, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 29, 2024	blackrock inc.	6.4%	1,809,377	SC 13G/A
May 10, 2023	fmr llc	-	0	SC 13G/A
Feb 14, 2023	avoro capital advisors llc	5.5%	1,410,000	SC 13G
Feb 14, 2023	redmile group, llc	7.4%	1,896,645	SC 13G/A
Feb 14, 2023	point72 asset management, l.p.	2.2%	556,252	SC 13G/A

Recent SEC filings of Krystal Biotech Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	8-K	Current Report
May 06, 2024	10-Q	Quarterly Report
May 06, 2024	8-K	Current Report
Apr 04, 2024	DEF 14A	DEF 14A
Apr 04, 2024	DEFA14A	DEFA14A
Mar 11, 2024	144	Notice of Insider Sale Intent
Mar 11, 2024	144	Notice of Insider Sale Intent
Mar 11, 2024	4	Insider Trading
Mar 11, 2024	4	Insider Trading
Mar 01, 2024	4	Insider Trading

Peers (Alternatives to Krystal Biotech Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Krystal Biotech Inc News

Latest updates

Krystal Biotech Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)							(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2018Q3	2018Q2
Revenue	7.4%	45,250,000	42,143,000	8,556,000	6,417,500	4,279,000	2,140,500	2,000
Operating Expenses	33.1%	51,934,000	39,005,500	34,549,000	38,048,000	48,823,000	2,972,000	2,449,000
S&GA Expenses	5.2%	26,058,000	24,764,500	23,697,000	25,904,000	24,035,000	1,058,000	924,000
R&D Expenses	-3.6%	10,957,000	11,370,000	10,629,000	12,144,000	12,288,000	1,914,000	1,525,000
EBITDA Margin	0%	0.35	0.35	-	-	-	-	-
EBT Margin	0%	0.25	0.25	-	-	-	-	-
Net Income	-89.3%	932,000	8,692,000	80,747,000	-33,210,000	-45,297,000	-2,755,000	-2,276,000
Net Income Margin	422.9%	1.13	0.22	-	-	-	-	-
Free Cashflow	261.1%	14,628,000	-9,079,000	-23,007,000	-36,980,000	-31,537,000	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	4.3%	853	818	790	684	532	558	576	601	617	626	451	444	443	311	311	318	205	209	214	205	116
Current Assets	2.4%	602	588	582	484	355	384	398	429	438	442	346	370	406	275	288	299	188	196	204	196	108
Cash Equivalents	0.2%	359	358	373	276	141	162	186	219	269	341	287	330	402	268	282	292	180	188	195	187	98.00
Inventory	58.0%	11.00	7.00	5.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-0.7%	160	161	164	164	163	162	158	151	137	112	79.00	45.00	34.00	31.00	18.00	13.00	10.00	8.00	7.00	6.00	4.00
Liabilities	36.1%	54.00	40.00	34.00	31.00	42.00	36.00	36.00	42.00	68.00	33.00	43.00	25.00	12.00	19.00	10.00	8.00	7.00	6.00	7.00	7.00	6.00
Current Liabilities	43.8%	48.00	33.00	28.00	24.00	35.00	29.00	28.00	34.00	60.00	26.00	36.00	18.00	9.00	15.00	7.00	6.00	4.00	3.00	4.00	4.00	3.00
Shareholder's Equity	2.6%	799	779	756	653	490	522	541	559	549	594	408	419	431	292	302	310	198	203	208	198	109
Retained Earnings	0.3%	-268	-269	-278	-359	-326	-280	-248	-218	-190	-140	-118	-103	-87.03	-71.21	-60.80	-51.22	-44.39	-39.05	-33.69	-29.42	-24.07
Additional Paid-In Capital	2.0%	1,068	1,048	1,035	1,013	816	804	791	780	741	735	527	522	518	363	363	361	243	242	241	228	134
Shares Outstanding	1.0%	29.00	28.00	28.00	28.00	26.00	26.00	26.00	25.00	25.00	22.00	22.00	22.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	2,800	-	-	-	1,400	-	-	-	1,200	-	-	-	595	-	-	-	454	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	319.7%	15,888	-7,232	-21,226	-34,190	-26,156	-22,329	-19,688	-43,059	-15,493	-20,900	-7,255	-10,129	-9,654	-8,024	-6,778	-5,054	-6,227	-7,000	-4,266	-4,209	-3,215
Share Based Compensation	-5.6%	9,299	9,853	8,312	11,331	10,437	9,552	9,059	8,189	6,430	5,145	3,666	4,195	2,313	570	1,356	807	539	323	278	325	313
Cashflow From Investing	-155.7%	-25,980	-10,160	105,192	-15,957	3,563	-5,208	-14,743	-38,224	-55,908	-126,540	-37,166	-62,317	-747	-6,217	-2,697	-962	-1,305	-591	-682	-1,236	-2,482
Cashflow From Financing	304.1%	10,583	2,619	13,388	185,269	1,474	3,069	2,120	30,700	-542	202,072	1,508	-199	144,304	141	166	117,469	243	299	13,167	94,019	40.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

KRYS Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Income Statement [Abstract]

Revenue from Contract with Customer, Product and Service [Extensible Enumeration]

Product [Member]

Product revenue, net

$ 45,250

$ 0

Expenses

Cost, Product and Service [Extensible Enumeration]

Product [Member]

Cost of goods sold

$ 2,419

$ 0

Research and development

10,957

12,288

Selling, general, and administrative

26,058

24,035

Litigation settlement

12,500

Total operating expenses

51,934

48,823

Loss from operations

(6,684)

(48,823)

Other income

Interest and other income, net

7,616

3,526

Net income (loss)

932

(45,297)

Unrealized (loss) gain on available-for-sale securities and other

(937)

^[1]

574

Comprehensive loss

$ (5)

$ (44,723)

Net income (loss) per common share: basic (in dollars per share)

$ 0.03

$ (1.76)

Net income (loss) per common share: diluted (in dollars per share)

$ 0.03

$ (1.76)

Weighted-average common shares outstanding: basic (in shares)

28,295,000

25,712,000

Weighted-average common shares outstanding: diluted (in shares)

29,291,000

25,712,000

[1]	Includes foreign currency translation losses of $62 thousand and $35 thousand for the three months ended March 31, 2024 and 2023, respectively.

KRYS Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 359,006	$ 358,328
Short-term investments	179,253	173,850
Accounts receivable, net	46,467	42,040
Inventory	11,037	6,985
Prepaid expenses and other current assets	6,485	6,706
Total current assets	602,248	587,909
Property and equipment, net	160,011	161,202
Long-term investments	83,996	61,954
Right-of-use assets	6,845	7,027
Other non-current assets	196	263
Total assets	853,296	818,355
Current liabilities
Accounts payable	5,359	4,132
Current portion of lease liability	1,430	1,474
Accrued rebates	11,289	5,977
Accrued expenses and other current liabilities	29,511	21,511
Total current liabilities	47,589	33,094
Lease liability	6,465	6,620
Total liabilities	54,054	39,714
Commitments and contingencies (see note 7)
Stockholders' equity
Common stock; $0.00001 par value; 80,000 shares authorized as of March 31, 2024 and December 31, 2023; 28,528 and 28,237 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.	0	0
Additional paid-in capital	1,068,436	1,047,830
Accumulated other comprehensive (loss) gain	(299)	638
Accumulated deficit	(268,895)	(269,827)
Total stockholders’ equity	799,242	778,641
Total liabilities and stockholders’ equity	$ 853,296	$ 818,355

About Krystal Biotech Inc

Krystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis. The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

CEO	Mr. Krish S. Krishnan M.B.A., M.S.
WEBSITE	krystalbio.com
INDUSTRY	Biotechnology
EMPLOYEES	210

Krystal Biotech Inc Frequently Asked Questions

What is the ticker symbol for Krystal Biotech Inc? What does KRYS stand for in stocks?

KRYS is the stock ticker symbol of Krystal Biotech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Krystal Biotech Inc (KRYS)?

As of Mon May 13 2024, market cap of Krystal Biotech Inc is 4.42 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KRYS stock?

You can check KRYS's fair value in chart for subscribers.

What is the fair value of KRYS stock?

You can check KRYS's fair value in chart for subscribers. The fair value of Krystal Biotech Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Krystal Biotech Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KRYS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Krystal Biotech Inc a good stock to buy?

The fair value guage provides a quick view whether KRYS is over valued or under valued. Whether Krystal Biotech Inc is cheap or expensive depends on the assumptions which impact Krystal Biotech Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KRYS.

What is Krystal Biotech Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, KRYS's PE ratio (Price to Earnings) is 77.24 and Price to Sales (PS) ratio is 87.09. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KRYS PE ratio will change depending on the future growth rate expectations of investors.